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The Impella® is a ventricular assist device used for temporary left ventricular
support and has been approved for use since 2008. In this report we present a
case of a patient who experienced mitral regurgitation as a complication shortly
after placement of an Impella® as well as a brief literature review. To our
knowledge this is the first such case demonstrating resolution of iatrogenic mitral
regurgitation with removal of the device as opposed to permanent damage.
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The Impella® (Abiomed, Denvers, MA) is a percutaneous left ventricular assist
device used for temporary left ventricular support. First approved for use in 2009,
the Impella® is now incorporated in five separate clinical practice guidelines as an
option for management of heart failure, cardiogenic shock, and in cardiac
transplant1,2,3,4,5. A recently published, single center report revealed this
technology as a viable option as a bridge to not only transplant but also durable
mechanical support6. Reported complications resulting from the use of the Impella®
devices (both 2.5 and 5.0) are hemolysis, pump failure, malposition, catheter kink,
aortic dissection, aortic valve damage, mitral valve damage, groin hematoma,
pseudoaneurysm, and acute limb ischemia. In this case, we report the first
instance of acute mitral regurgitation due to entrapment of the drive line in the
chordal apparatus which resolved with removal of the device.
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Case Report
The patient is a 71-year-old Caucasian male with coronary artery disease with four
vessel coronary artery bypass, hypertension, hyperlipidemia, type 2 diabetes
mellitus, morbid obesity with multiple prior admissions for decompensated systolic
heart failure. The Patient initially presented to an outside hospital with multiple
syncopal episodes. He was in atrial fibrillation, with diffuse ST elevation in the chest
leads on the electrocardiogram. On coronary angiogram, there was a multivessel
disease, with the only patent vessel being a diagonal branch. The estimated
ejection fraction was 10-15%. Revascularization of the LIMA graft was attempted
but unsuccessful. An intra-aortic balloon pump was placed at that time and the
patient was then transferred to our institution for evaluation for left ventricular assist
device placement.
Upon arrival, the patient was in cardiogenic shock with hypotension, acidosis and
renal failure requiring high doses of vasopressor support. He was placed on
venoarterial extracorporeal membranous oxygenation (VA ECMO) to facilitate
recovery from end-organ damage and as a bridge to evaluation for left ventricular
assist device. On hospital day five he was transitioned to a right subclavian
Impella® 5.0 to facilitate ambulation and rehabilitation prior to definitive left
ventricular assist device placement. Proper positioning of the device was difficult
due to a small left ventricular cavity size. Concomitant transthoracic echocardiogram
revealed low ejection fraction as already noted at the outside hospital as well as no
evidence of valvular pathology; specifically, no mitral regurgitation (Figure 1).

Figure 1. A transthoracic, two chamber echocardiographic view prior to any
mechanical circulatory support showing trivial mitral regurgitation.
Shortly after Impella® placement, the patient experienced a pulseless electrical
activity cardiac arrest and underwent emergent cannulation with VA ECMO. A
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transesophageal echocardiogram was performed which demonstrated the Impella®
tangled in the mitral apparatus causing restriction of mitral valve leaflet motion as
well as severe mitral regurgitation (Figures 2 and 3, Video 1:
https://vimeo.com/208673728 and 2: https://vimeo.com/208673681).

Figure 2. A trans-esophageal, mid-esophageal, 3-chamber view depicting the
pigtail of the Impella® entangled in the mitral subvalvular apparatus.

Figure 3. A color Doppler of a trans-esophageal, mid-esophageal, 3-chamber view
depicting severe mitral regurgitation with associated pigtail of the Impella®
entangled in mitral subvalvular apparatus resulting in restricted closure of anterior
mitral valve leaflet
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The most likely reason for this to have occurred is that the device was either
inserted or migrated deep in to the left ventricular cavity resulting the entrapment of
the pigtail catheter of the Impella in mitral valvular apparatus. Attempts at
repositioning the device into the left ventricle apex were unsuccessful. The device
continued to have malfunction alarms and was ultimately removed with resolution
of mitral regurgitation (Figure 4, Video 3: https://vimeo.com/208673780 and 4:
https://vimeo.com/208673969).

Figure 4. A color Doppler of a trans-esophageal, mid-esophageal, 2-chamber
(commissural) view depicting resolution of severe mitral regurgitation after
withdrawal of the Impella® device with subsequent adequate apposition of mitral
valve leaflets.
The patient was continued on ECMO support until hospital day 19 when he
underwent LVAD placement and was ultimately discharged about 40 days later.
Unfortunately, he was readmitted 17 days later for acute on chronic systolic heart
failure which was further complicated by a stroke and he passed away shortly after
the decision was made to withdraw care.

Discussion
The Impella® 5.0 is a feasible alternative to more invasive extracorporeal assist
devices (ECMO). The device can be placed by arterial cut-down in either the
femoral or axillary artery, although the latter is preferred to allow mobility during
device support. In addition to ambulatory potential associated with Impella® 5.0
support, certain patient populations may benefit from this device more so than
ECMO due to the physiologic benefit of reducing myocardial oxygen consumption.
This is due to the Impella® Support resulting in a leftward shift of the pressurevolume Loop ultimately leading to a marked reduction in pressure-volume area as
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well as marked decrease in left ventricular end diastolic pressure and thus resulting
in decreased myocardial oxygen consumption. These properties may be of
particular interest for patients with cardiogenic shock, who would benefit from this
aspect of Impella® technology more so than ECMO support. To date, there is only
one prospective study evaluating the Impella® 5.0, which ultimately led to its
approval. This study, along with a larger (albeit retrospective) analysis similarly
demonstrated that when compared to ECMO there is similar success in terms of
weaning, successful bridging to destination support, and overall survival.
Interestingly, the RECOVER I study experienced a relatively low rate of adverse
events: the only safety end points were death and stroke, of which there were one
of each, and one patient of the sixteen in the study experienced hemolysis
although the investigators did not establish relatedness to the use of the device. A
newer prospective study enrolling 40 patients had zero strokes or major bleeding
events but reported a significant rate of acute renal dysfunction (33%), bleeding
requiring transfusion (28%), and device malfunction (70%)3. Due to the relatively
recent incorporation of percutaneous left ventricular assist devices in the
management of heart failure and cardiogenic shock, the body of literature related to
their use is still growing. There are individual case reports for complications with
use of the Impella® relating to the mitral apparatus and have consisted of both
mitral regurgitation and mitral stenosis7,8,9. To our knowledge this is a first published
case of reversal of mitral regurgitation with withdrawal of the device. One
observation we have made is that the complications in the aforementioned case
reports as well as our experience, involved the use of an Impella® LP 5.0, which is
possibly a consequence of the device’s larger size compared to that of the Impella®
2.5.
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